BSX
$41.58-1.45%
as of close, Oct 7, 2026
☾ AH $41.58 -1.45%
Boston Scientific CorporationStock · HealthcareS&P 500 Equal Weight 0.2%S&P 500 0.10%Russell 1000 0.09%US Stock Market 0.09%Russell 3000 0.09%MSCI World 0.08%MSCI ACWI 0.07%
BSX — Boston Scientific Corporation price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
30.040.050.060.070.080.090.0100.00100.0M200.0M$41.58—20162019202120242026
2026-10-07
Price$41.58
MA20$48.11
MA50$73.28
Vol78.4M
Key stats#
Price data
- Price
- $41.58
- YTD price return
- -56.39%
- YTD total return
- -56.39%
- Next earnings
- Oct 28, 2026 · Before open
- Market cap
- 60.3B
- Enterprise value
- 73.3B
- Shares outstanding
- 1.4B
- 52W low
- $41.50
- 52W high
- $105.65
- From 52W high
- -60.64%
- From 52W low
- +0.19%
- 52W range
- 0%
- Beta
- 0.57
Volume
- Rel volume
- 0.78×
- 30D volume
- 20.2M
- 30D $ vol
- 904.7M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- +$9.5M
- Insider net 1Y
- −$5.0M
Form 4 transactions by trade date, as filed; latest on file 2026-08-25.
Fundamentals
- Sales (ttm)
- 21B
- Sales/share
- $14.49
- EPS (ttm)
- $2.46
- FCF (ttm)
- 3.6B
- FCF/share
- $2.50
- Book value/share
- $17.20
- Net margin
- 17.47%
- ROE
- 14.72%
- ROA
- 8.11%
- Debt / equity
- 0.44×
- Current ratio
- 1.24
Growth (CAGR, ttm) · 10Y
- Sales
- +13.54%+16.14%+13.40%+9.70%
- Net income
- +46.98%+59.03%+44.53%n/a
- FCF
- +4.02%+33.92%+14.35%+12.96%
- Shares
- -2.20%-0.34%+0.35%+0.63%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +47.04%+57.44%+43.35%n/a
- Sales/share
- +16.09%+16.54%+13.00%+9.01%
- FCF/share
- +6.36%+34.38%+13.95%+12.25%
- Book value/share
- +13.71%+11.38%+8.97%+14.17%
- Dividend/share
- -75.04%-31.44%n/an/a
- Price
- -56.67%-7.25%-0.95%+5.88%
- Total return
- -56.67%-7.25%-0.95%+5.88%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 16.9×
- P/OI (ttm)
- 14.5×
- Fwd P/E
- 12.4×
- P/S (ttm)
- 2.9×
- P/B (mrq)
- 2.4×
- P/FCF (ttm)
- 16.6×
- EV/EBITDA (fy)
- 13.2×
- EV/Sales (ttm)
- 3.5×
- FCF yield (ttm)
- 6.02%
- Buyback yield (realized, 1y)
- 2.20%
- Shareholder yield (realized, 1y)
- 2.20%
- Buyback yield (cash, ttm)
- 3.32%
- Shareholder yield (cash, ttm)
- 3.32%
Vs own 10Y history
- P/E
- 10th
- P/OI
- 0th
- P/S
- 0th
- P/B
- 0th
- P/FCF
- 0th
Bar = where today’s multiple sits in BSX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-07#
1D
-1.45%
5D
-4.74%
1M
-13.01%
3M
-8.21%
YTD
-56.39%
1Y
-56.64%
5Y
-4.68%
Recent filings#
- Oct 78-K · Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Sep 88-K · Material cybersecurity incident
- Aug 25Insider buy · Morano Susan E (Director) bought 2,040 shares for $100K at $49.22
- Aug 5Insider buy · Habiger David C (Director) bought 3,282 shares for $157K on 3 days since Aug 3
- Aug 3Insider buy · Mahoney Michael F (Chairman, President & CEO · Director) bought 186,240 shares for $9.0M at $48.33
Financial statements
Open full BSX financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +3.42% | +2.70% |
| JNJ | Johnson & Johnson | -6.10% | +1.44% |
| ABBV | AbbVie Inc. | +5.81% | +1.75% |
| MRK | Merck & Co. Inc. | -5.02% | +0.60% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -5.33% | -0.09% |
| TMO | Thermo Fisher Scientific Inc. | +7.87% | +0.83% |
| AMGN | Amgen Inc. | -5.52% | +2.60% |
| GILD | Gilead Sciences Inc. | -2.75% | +1.82% |
